Cargando…

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial

Individuals with IPF who follow a MUFA diet report a lower incidence of pirfenidone gastrointestinal adverse events than those that follow a SFA diet, which could explain the different prevalence in GI pirfenidone AEs reported by countries in IPF cohorts https://bit.ly/3LuzAUJ

Detalles Bibliográficos
Autores principales:	Molina-Molina, Maria, Shull, Jessica Germaine, Vicens-Zygmunt, Vanesa, Rivera-Ortega, Pilar, Antoniou, Katerina, Bonella, Francesco, Renzoni, Elisabetta, Russell, Anne-Marie, Maher, Toby M., Vancheri, Ada, Bachs, Anna, Avilés, Victoria, Palma, Josep, Bermudo, Guadalupe, Suarez-Cuartin, Guillermo, Tebé, Cristian, Rigo-Bonnin, Raul, Montes-Worboys, Ana, Wijsenbeek, Marlies, Vancheri, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586233/ https://www.ncbi.nlm.nih.gov/pubmed/37857429 http://dx.doi.org/10.1183/13993003.00262-2023

Ejemplares similares

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome
por: Bordas-Martínez, Jaume, et al.
Publicado: (2021)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
por: Bordas-Martinez, Jaume, et al.
Publicado: (2021)

Effects of Early Physical Therapy and Follow-Up in Acute Severe Coronavirus Disease 2019 Pneumonia: A Retrospective Observational Study
por: Bordas-Martínez, Jaume, et al.
Publicado: (2022)

Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?
por: Kalluri, Meena, et al.
Publicado: (2021)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
por: Maher, Toby M., et al.
Publicado: (2017)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2016)

Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2018)

Research highlights from the 2018 ERS International Congress: interstitial lung diseases
por: Alfaro, Tiago M., et al.
Publicado: (2019)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis
por: Wijsenbeek, Marlies S., et al.
Publicado: (2015)

ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly
por: Dupin, Clairelyne, et al.
Publicado: (2020)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
por: Miedema, Jelle R., et al.
Publicado: (2022)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

Erratum to: Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly
por: Guler, Sabina A., et al.
Publicado: (2022)

Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study
por: Wijsenbeek, Marlies, et al.
Publicado: (2018)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis
por: Maldonado, Mariel, et al.
Publicado: (2018)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Coronary Microvascular Dysfunction
por: Vancheri, Federico, et al.
Publicado: (2020)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Coronary Atherosclerosis Imaging
por: Henein, Michael Y., et al.
Publicado: (2020)

Mental Stress and Cardiovascular Health—Part I
por: Vancheri, Federico, et al.
Publicado: (2022)

The Impact of Mental Stress on Cardiovascular Health—Part II
por: Henein, Michael Y., et al.
Publicado: (2022)

When to start and when to stop antifibrotic therapies
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2017)

The Role of Inflammation in Cardiovascular Disease
por: Henein, Michael Y., et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis and cancer: do they really look similar?
por: Vancheri, Carlo
Publicado: (2015)

Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction
por: Planas-Cerezales, Lurdes, et al.
Publicado: (2021)

The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus
por: Tzouvelekis, Argyris, et al.
Publicado: (2021)

Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2019)

Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k6bsg32mq7hncidk9toomqn5ma